指南与共识心脑血管急症重症综合管理与镇静镇痛

重症成人新发心房颤动——SSAI临床实践指南

New-onset atrial fibrillation in critically ill adult patients-an SSAI clinical practice guideline.
指南 / 共识 · Acta Anaesthesiol Scand · 2023-05-24
一句话结论SSAI指南:重症成人新发房颤证据极为有限,弱推荐不常规使用治疗剂量抗凝,最佳实践声明为出院后由心脏科医生常规随访。

该指南由SSAI按GRADE方法制定,针对重症成人新发房颤(NOAF)提出4个临床问题:一线药物选择、血流动力学不稳定时是否直流电复律、是否抗凝、出院后是否随访。结果未检索到针对预设PICO问题的随机临床试验直接或间接证据,仅能提出1条弱推荐(不常规使用治疗剂量抗凝)和1条最佳实践声明(出院后由心脏科医生常规随访),对一线药物及直流电复律未能提出推荐。作者结论为证据极为有限且实践差异显著。

要点

  • 弱推荐不常规使用治疗剂量抗凝治疗重症成人NOAF(原文唯一一条弱推荐)。
  • 最佳实践声明:重症成人NOAF患者出院后由心脏科医生常规随访。
  • 对重症成人NOAF最佳一线药物选择,指南未能提出任何推荐。
  • 对血流动力学不稳定由NOAF所致者是否行直流电复律,指南未能提出任何推荐。
  • 证据体极为有限,未识别到针对预设PICO问题的随机临床试验直接或间接证据,实践差异显著。

适用人群与场景

  • 重症成人新发心房颤动(NOAF)患者。

处置流程与药物剂量

  • 弱推荐不常规使用治疗剂量抗凝治疗重症成人NOAF。
  • 最佳实践声明:重症成人NOAF患者出院后由心脏科医生常规随访。

研究设计与关键结果

  • 指南按GRADE方法制定,提出4个临床问题:一线药物选择、血流动力学不稳定时是否直流电复律、是否抗凝、出院后是否随访;评估死亡率、血栓栓塞事件和不良事件等患者重要结局,患者及家属参与指南小组。
  • 证据数量和质量非常有限,未识别到针对预设PICO问题的随机临床试验直接或间接证据。
  • 提出1条弱推荐:不常规使用治疗剂量抗凝治疗;1条最佳实践声明:出院后由心脏科医生常规随访。
  • 对最佳一线药物选择及血流动力学不稳定由NOAF所致者是否行直流电复律,未能提出任何推荐。

证据类型、等级与局限

  • 证据类型:临床实践指南(按GRADE方法制定)。
  • 证据数量和质量非常有限,未识别到针对预设PICO问题的随机临床试验直接或间接证据。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对重症成人NOAF,不常规使用治疗剂量抗凝(弱推荐)。
  • 重症成人NOAF患者出院后由心脏科医生常规随访(最佳实践声明)。
  • 对一线药物选择及血流动力学不稳定时是否直流电复律,原文未据此给出推荐。

指南或共识出处

  • SSAI临床实践指南:重症成人新发心房颤动(New-onset atrial fibrillation in critically ill adult patients-an SSAI clinical practice guideline),发表于Acta Anaesthesiol Scand。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Acute or new-onset atrial fibrillation (NOAF) is the most common cardiac arrhythmia in critically ill adult patients, and observational data suggests that NOAF is associated to adverse outcomes.

METHODS: We prepared this guideline according to the Grading of Recommendations Assessment, Development and Evaluation methodology. We posed the following clinical questions: (1) what is the better first-line pharmacological agent for the treatment of NOAF in critically ill adult patients?, (2) should we use direct current (DC) cardioversion in critically ill adult patients with NOAF and hemodynamic instability caused by atrial fibrillation?, (3) should we use anticoagulant therapy in critically ill adult patients with NOAF?, and (4) should critically ill adult patients with NOAF receive follow-up after discharge from hospital? We assessed patient-important outcomes, including mortality, thromboembolic events, and adverse events. Patients and relatives were part of the guideline panel.

RESULTS: The quantity and quality of evidence on the management of NOAF in critically ill adults was very limited, and we did not identify any relevant direct or indirect evidence from randomized clinical trials for the prespecified PICO questions. We were able to propose one weak recommendation against routine use of therapeutic dose anticoagulant therapy, and one best practice statement for routine follow-up by a cardiologist after hospital discharge. We were not able to propose any recommendations on the better first-line pharmacological agent or whether to use DC cardioversion in critically ill patients with hemodynamic instability induced by NOAF. An electronic version of this guideline in layered and interactive format is available in MAGIC: https://app.magicapp.org/#/guideline/7197.

CONCLUSIONS: The body of evidence on the management of NOAF in critically ill adults is very limited and not informed by direct evidence from randomized clinical trials. Practice variation appears considerable.

来源:Acta Anaesthesiol Scand,查看原文。版权归原作者所有。

参考来源

  1. Andreasen AS, Wetterslev M, Sigurdsson MI, et al. New-onset atrial fibrillation in critically ill adult patients-an SSAI clinical practice guideline. Acta Anaesthesiol Scand. 2023. PMID: 37289426. doi:10.1111/aas.14262

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。